Literature DB >> 2884111

MPTP-induced parkinsonian model in mice: biochemistry, pharmacology and behavior.

N Ogawa, K Mizukawa, Y Hirose, S Kajita, S Ohara, Y Watanabe.   

Abstract

The effects of MPTP administered to mice were examined biochemically and pharmacologically. The dopamine level in the striatum of the mice injected with MPTP decreased markedly, but recovered to 50% of the control level 6 weeks later. Amine fluorescence showed a decrease in the amount of amine especially in the lateral part of the striatum. Of the four neuropeptides, only the concentration of somatostatin changed with time. These findings indicate that the time elapsed after MPTP treatment should be taken into consideration when MPTP-treated mice are used as a parkinsonism model. Six weeks after MPTP treatment, the concentration of the striatal muscarinic cholinergic receptor decreased significantly but recovered to the normal level after the administration of L-dopa. Such a change was not detected with the dopamine D2-receptor. The therapeutic efficacy of medication in MPTP-treated mice as examined by the pole test showed that L-threo-3,4-dihydroxyphenylserine (L-threo-DOPS), which is considered to be the precursor of norepinephrine, enhances the effect of L-dopa.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2884111     DOI: 10.1159/000116351

Source DB:  PubMed          Journal:  Eur Neurol        ISSN: 0014-3022            Impact factor:   1.710


  17 in total

1.  The yeast product Milmed enhances the effect of physical exercise on motor performance and dopamine neurochemistry recovery in MPTP-lesioned mice.

Authors:  Trevor Archer; Anders Fredriksson
Journal:  Neurotox Res       Date:  2013-07-27       Impact factor: 3.911

2.  Ahr and Cyp1a2 genotypes both affect susceptibility to motor deficits following gestational and lactational exposure to polychlorinated biphenyls.

Authors:  Breann T Colter; Helen Frances Garber; Sheila M Fleming; Jocelyn Phillips Fowler; Gregory D Harding; Molly Kromme Hooven; Amy Ashworth Howes; Smitha Krishnan Infante; Anna L Lang; Melinda Curran MacDougall; Melinda Stegman; Kelsey Rae Taylor; Christine Perdan Curran
Journal:  Neurotoxicology       Date:  2018-03       Impact factor: 4.294

3.  Behavioral effects of dopaminergic agonists in transgenic mice overexpressing human wildtype alpha-synuclein.

Authors:  S M Fleming; J Salcedo; C B Hutson; E Rockenstein; E Masliah; M S Levine; M-F Chesselet
Journal:  Neuroscience       Date:  2006-08-23       Impact factor: 3.590

4.  The effect of docosahexaenoic Acid on visual evoked potentials in a mouse model of Parkinson's disease: the role of cyclooxygenase-2 and nuclear factor kappa-B.

Authors:  Ozlem Ozsoy; Gamze Tanriover; Narin Derin; Nimet Uysal; Necdet Demir; Burcu Gemici; Ceren Kencebay; Piraye Yargicoglu; Aysel Agar; Mutay Aslan
Journal:  Neurotox Res       Date:  2011-01-14       Impact factor: 3.911

5.  Abnormalities of motor function, transcription and cerebellar structure in mouse models of THAP1 dystonia.

Authors:  Marta Ruiz; Georgina Perez-Garcia; Maitane Ortiz-Virumbrales; Aurelie Méneret; Andrika Morant; Jessica Kottwitz; Tania Fuchs; Justine Bonet; Pedro Gonzalez-Alegre; Patrick R Hof; Laurie J Ozelius; Michelle E Ehrlich
Journal:  Hum Mol Genet       Date:  2015-09-16       Impact factor: 6.150

Review 6.  Proteomics in animal models of Alzheimer's and Parkinson's diseases.

Authors:  Renã A Sowell; Joshua B Owen; D Allan Butterfield
Journal:  Ageing Res Rev       Date:  2008-07-18       Impact factor: 10.895

7.  Effects of chronic bifemelane hydrochloride administration on receptors for N-methyl-D-aspartate in the aged-rat brain.

Authors:  N Ogawa; K Mizukawa; K Haba; M Asanuma; A Mori
Journal:  Neurochem Res       Date:  1992-07       Impact factor: 3.996

8.  Neurotrophic effects of Cerebrolysin in the Mecp2(308/Y) transgenic model of Rett syndrome.

Authors:  Edith Doppler; Edward Rockenstein; Kiren Ubhi; Chandra Inglis; Michael Mante; Anthony Adame; Leslie Crews; Monika Hitzl; Herbert Moessler; Eliezer Masliah
Journal:  Acta Neuropathol       Date:  2008-07-04       Impact factor: 17.088

9.  Progressive dopaminergic degeneration in the chronic MPTPp mouse model of Parkinson's disease.

Authors:  Nicoletta Schintu; Lucia Frau; Marcello Ibba; Arianna Garau; Ezio Carboni; Anna R Carta
Journal:  Neurotox Res       Date:  2009-05-27       Impact factor: 3.911

10.  Toll-like receptor 4 promotes α-synuclein clearance and survival of nigral dopaminergic neurons.

Authors:  Nadia Stefanova; Lisa Fellner; Markus Reindl; Eliezer Masliah; Werner Poewe; Gregor K Wenning
Journal:  Am J Pathol       Date:  2011-06-14       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.